Ivosidenib

Tibsovo (ivosidenib tablets) is a precision medicine that targets a specific type of mutation known as isocitrate dehydrogenase 1 (IDH1). Tibsovo is approved in five indications globally, including approvals in the U.S., European Union, Australia, and China.
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation.
Fifth approved indication for Tibsovo solidifies Servier’s leadership in mutant IDH inhibition.